Free Trial
NASDAQ:GOSS

Gossamer Bio Q4 2023 Earnings Report

Gossamer Bio logo
$0.84 +0.01 (+1.19%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$0.86 +0.02 (+2.50%)
As of 04/17/2025 05:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gossamer Bio EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.21
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Gossamer Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Gossamer Bio Announcement Details

Quarter
Q4 2023
Time
Q4 2023 Earnings Release
Conference Call Date
Tuesday, March 5, 2024
Conference Call Time
7:31AM ET

Upcoming Earnings

Gossamer Bio's Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Gossamer Bio Earnings Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More Gossamer Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Gossamer Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gossamer Bio and other key companies, straight to your email.

About Gossamer Bio

Gossamer Bio (NASDAQ:GOSS), a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

View Gossamer Bio Profile

More Earnings Resources from MarketBeat